Cimeio Therapeutics

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeios proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders

Cimeio therapeutics operates in the Biotechnology research industry.

Cimeio therapeutics's revenue is 1m - 10m

Cimeio therapeutics has 11 - 50 employees.